NUZOLVENCE

Launch

zoliflodacin

NDAORALFOR SUSPENSIONPriority Review

Approved

Dec 2025

Lifecycle

Launch

Competitive Pressure

0/100

Clinical Trials

NCT03613649Phase 1Completed

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Started Sep 2018

LOE Date

Jan 21, 2034

96 months away

Patent Expiry

Jan 21, 2034

Exclusivity Expiry

Dec 12, 2035

Patent #	Expiry	Type	Use Code
9040528	Oct 13, 2029		U-4369
8658641	Jun 20, 2030	Substance	—
8889671	Jan 21, 2034	Substance	U-4369
9187495	Jan 21, 2034	Substance	U-4369
9540394	Jan 21, 2034		U-4369

External Resources